The Global Drug Infusion Systems Market is estimated to reach over USD 23.27 billion by 2030, exhibiting a CAGR of 8.3% during the forecast period. An infusion system is a pump used to administer fluids, nutrients, or medications to a patient's circulatory system. It's usually given intravenously but occasionally used for epidural and arterial infusions. It's often used to manage or treat illnesses or disorders in the neurological system. Increased demand for infusion pumps for infusing drugs or other essential fluids, rising prevalence of fatal diseases and chronic diseases, increased demand for infusion pumps in military and medical units, and advancements in the technology of these surgical drug infusion systems from key market players are all contributing to the global infusion system market's growth. The growing number of chronic diseases, as well as the globe's rapidly ageing population, the ever-increasing demand for ambulatory infusion pumps, and the increasing volume of surgical procedures conducted around the world, are all propelling the infusion pumps market ahead. However, concerns about the systems' consequences and low-income countries' inability to purchase such systems for their medical units are the main roadblocks to the expansion of the global infusion system.
Global Drug Infusion Systems Market is categorized based on product type and application. Based on product, the market is segmented as Large Volume Infusion Systems, Patient Controlled Analgesia, Elastomeric Infusion Pumps, Insulin Infusion Pumps, Syringe Infusion Systems, Implantable Infusion Systems, Ambulatory Infusion Systems, and Enteral Infusion Systems. By application, the market is segmented into Oncology/Chemotherapy, Diabetes, Analgesia, Nutrition, Haematology, Paediatrics, and Other Applications.
Based on application, the diabetes segment is accounted as a major contributor to the Global Drug Infusion Systems Market.
The global drug infusion systems market is divided into paediatrics, diabetes, nutrition, haematology, analgesia, chemotherapy, and others based on application. The diabetes segment is anticipated to lead in terms of revenue share contribution to the worldwide drug infusion systems market during the projected period. Increased use of drug infusion systems for insulin delivery to diabetic patients and an increase in the number of diabetic patients worldwide are driving this segment's expansion. However, revenue growth in the paediatrics category is expected to be strong during the projection period. In the United States, medication overdoses are a major source of concern for healthcare practitioners and providers. Medication errors have been demonstrated to have a more significant impact on paediatric patients, and healthcare professionals are increasingly employing drug infusion systems to reduce the occurrence of medication errors in paediatric patients, which is projected to drive revenue growth in this category.
The insulin Infusion Pumps segment witnessed growth at a rapid rate.
Large Volume Infusion Systems, Patient Controlled Analgesia, Elastomeric Infusion Pumps, Insulin Infusion Pumps, Syringe Infusion Systems, Implantable Infusion Systems, Ambulatory Infusion Systems, and Enteral Infusion Systems are the product segments of the market. The category is expected to maintain its dominance by expanding significantly during the forecast period. This is due to an increase in the number of type 1 diabetic patients worldwide and the launch of promising technology in the insulin pump field. In the coming years, growing applications of PCA pumps in pain management are expected to drive global product demand.
The North America Global Drug Infusion Systems Market holds a significant revenue share in the region.
Regionally, North America is projected to account for a significant share of the Global Drug Infusion Systems Market in the forecasted period. Higher diabetes diagnosis and treatment rates, increased use of ambulatory pumps, and good reimbursement policies characterize the market in the region. The improvement of medical device technology in the North America region is driving the region's growth. Europe has the second-largest market share. During the period 2022-2030, an increase in the prevalence of chronic diseases in this region, as well as significant expenditure in the healthcare sector by the European Commission, is expected to drive demand for these pumps in Europe. However, the market in growing regions such as Asia Pacific, Latin America, the Middle East and Africa is expected to grow at a faster rate during the projection period. Increased prevalence of chronic diseases such as diabetes and cancer, expanding healthcare infrastructure, rising GDP, increased disposable income, and increased awareness of advanced therapies' availability in the Asia Pacific region are some of the factors expected to drive market growth in the coming years. Latin America's, the Middle East's, and Africa's markets are still in their infancy. Leading businesses' increased focus on expanding their presence, on the other hand, will boost the market in these regions.
The global drug infusion systems market is highly fragmented, with a small number of large and medium-sized companies accounting for most sales. Key players are pursuing various strategies, including mergers and acquisitions, strategic agreements and contracts, and the adoption of more advanced technologies in drug infusion systems solutions. They are also developing, testing, and introducing new and more efficient systems to the market. The following are some of the most well-known players in the worldwide drug infusion systems market: Acromed AG, B. Braun, Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Caesarea Medical Electronics Ltd., Debiotech S.A., Flowonix Medical Inc., Fresenius SE & Co. KGaA, Halyard Health, Inc., ICU Medical Inc., IRADIMED CORPORATION, Insulet Corporation, Medtronic Public Limited Company, MOOG, Inc., Smiths Group plc, Tandem Diabetes Care, Inc., Terumo Corporation, and Zyno Medical, LLC".